We are live on ! Find out more
PRAH

PRA Health Sciences, Inc.
PRAH

Delisted

PRAH was delisted on the 30th of June, 2021.

334 hedge funds and large institutions have $6B invested in PRA Health Sciences, Inc. in 2018 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 126 increasing their positions, 128 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 128

8% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 49

2% less funds holding

Funds holding: 342334 (-8)

14% less capital invested

Capital invested by funds: $7.01B → $6B (-$1.02B)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

53% less call options, than puts

Call options by funds: $3.59M | Put options by funds: $7.67M

Holders
334
Holders Change
-8
Holders Change %
-2.34%
% of All Funds
7.44%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
45
Increased
126
Reduced
128
Closed
49
Calls
$3.59M
Puts
$7.67M
Net Calls
-$4.08M
Net Calls Change
+$2.77M
Name Holding Trade Value Shares
Change
Change in
Stake
PWMG
326
Prestige Wealth Management Group
New Jersey
$1K +$607 +6 New
SFSIG
327
San Francisco Sentry Investment Group
California
$1K +$809 +8 New
MSA
328
Marino Stram & Associates
Massachusetts
$1K +$1.11K +11 New
LC
329
Lindbrook Capital
California
$1K +$1.21K +12 New
CFGS
330
Concourse Financial Group Securities
Alabama
$1K +$1.62K +16 New
QCG
331
Quadrant Capital Group
Ohio
$1K +$2.02K +20 New
AAMU
332
Amundi Asset Management US
Massachusetts
$147 -$1.49M -14,724 -90%
GT
333
Glenmede Trust
Pennsylvania
$23 +$25.7K +254 New
HH
334
HWG Holdings
Texas
-$5.92M -53,710 Closed
PCM
335
Penserra Capital Management
California
-$5.88M -53,407 Closed
SIM
336
Spark Investment Management
New York
-$3.25M -29,500 Closed
RA
337
Royce & Associates
New York
-$3.18M -28,836 Closed
BCM
338
BlueCrest Capital Management
Jersey
-$3.1M -28,152 Closed
Pacer Advisors
339
Pacer Advisors
Pennsylvania
-$2.31M -20,970 Closed
ERSOT
340
Employees Retirement System of Texas
Texas
-$1.87M -17,000 Closed
PI
341
PEAK6 Investments
Illinois
-$1.59M -14,459 Closed
Capital Fund Management (CFM)
342
Capital Fund Management (CFM)
France
-$1.12M -10,159 Closed
LMGAM
343
Liberty Mutual Group Asset Management
Massachusetts
-$1.11M -10,080 Closed
BCM
344
Beck Capital Management
Texas
-$827K -7,507 Closed
CANY
345
Caxton Associates (New York)
New York
-$759K -6,892 Closed
PAG
346
Private Advisor Group
New Jersey
-$756K -6,858 Closed
Teacher Retirement System of Texas
347
Teacher Retirement System of Texas
Texas
-$746K -6,770 Closed
VF
348
Virtu Financial
New York
-$746K -6,766 Closed
PP
349
Paloma Partners
Connecticut
-$673K -6,100 Closed
RJFSA
350
Raymond James Financial Services Advisors
Florida
-$667K -6,049 Closed

PRAH Hedge Fund Activity: Q4 2018 in Review

334 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in PRA Health Sciences, Inc. (PRAH) for Q4 2018, worth a combined $6B — down 14% from $7.01B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of PRAH and 45 opened new positions — a net loss of 4 holders — while 128 trimmed existing stakes and 126 added.

The largest buyer was Pendal Group, opening a new position worth an estimated $89.4M. The largest seller was Laurion Capital Management, cutting an estimated $48.1M.

  • 334 institutional investors held PRA Health Sciences, Inc. (PRAH) as of Q4 2018, down from 342 in Q3 2018.
  • Funds reported $6B of PRA Health Sciences, Inc. stock for Q4 2018, down 14% quarter-over-quarter.
  • 45 funds opened new PRA Health Sciences, Inc. positions in Q4 2018 and 49 closed out, a net change of -4 holders.
  • The largest PRA Health Sciences, Inc. buyer in Q4 2018 was Pendal Group, an estimated $89.4M added.
  • The largest PRA Health Sciences, Inc. seller in Q4 2018 was Laurion Capital Management, an estimated $48.1M sold.

Based on aggregated 13F filings for Q4 2018.